Business Wire

Adaptive Biotechnologies Announces a Collaboration with Amgen to Advance Clinical Development of the clonoSEQ® Assay in Multiple Myeloma

Jaa

Adaptive Biotechnologies, a leader in combining next-generation sequencing (NGS) and sophisticated bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announces it has entered into a collaboration agreement with Amgen to utilize Adaptive’s NGS-based clonoSEQ Assay in the Phase 3 CANDOR study, sponsored by Amgen in collaboration with Janssen, comparing Kyprolis® (carfilzomib), Darzalex® (daratumumab), and dexamethasone with Kyrpolis and dexamethasone. Adaptive’s NGS-based clonoSEQ Assay will be utilized to measure minimal residual disease (MRD) status in patients with relapsed or refractory Multiple Myeloma (MM).

“Incorporating MRD measurement by the clonoSEQ Assay offers Amgen the ability to accurately assess the depth of response generated by Kyprolis treatment in patients with relapsed or refractory MM,” said Chad Robins, President, CEO and Co-Founder of Adaptive Biotechnologies. “This is the second collaboration with Amgen to assess MRD in oncology clinical studies, and we are thrilled to continue to expand our work with such an industry-leading partner.”

Announced in January, the first collaboration with Amgen assesses MRD in patients with Acute Lymphoblastic Leukemia (ALL). Through this second collaboration, the companies will work towards further demonstrating the clinical utility of MRD detection in patients with relapsed or refractory MM treated with Kyprolis.

About Minimal/Measurable Residual Disease

Minimal/measurable residual disease (MRD) in hematologic malignancies refers to cancer cells that remain in the body of a person with cancer after treatment. These cells can be present at levels undetectable by traditional morphologic, microscopic examination of blood, bone marrow or a lymph node biopsy. Sensitive molecular technologies, such as next-generation sequencing utilized by the Adaptive Biotechnologies clonoSEQ Assay, are needed for reliable detection of MRD at levels below the limits of traditional assessment.

About the clonoSEQ ®  Assay

The Adaptive Biotechnologies clonoSEQ Assay enables physicians to utilize a molecular, next-generation sequencing-based minimal/measureable residual disease (MRD) detection method. The clonoSEQ Assay detects and quantifies DNA sequences found in malignant cells which can be tracked throughout treatment. This robust assay provides consistent, accurate measurement of disease burden which potentially allows physicians to visualize response to treatment over time. Adaptive intends to seek 510(K) marketing authorization from FDA for the clonoSEQ Assay.

About Adaptive Biotechnologies ®

Adaptive Biotechnologies is a pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive’s mission is to translate immunosequencing discoveries into clinical diagnostics and therapeutics to improve patient care. For more information, please visit adaptivebiotech.com.

Contact information

Adaptive Biotechnologies
Beth Keshishian
917-912-7195
media@adaptivebiotech.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Elliott Advisors (UK) Limited Statement on Telecom Italia26.4.2018 22:49Tiedote

Elliott Advisors (UK) Limited (“Elliott”) today sent a new letter and a presentation to Telecom Italia (“TIM” or the “Company”) shareholders calling upon shareholders to uphold best practice governance principles at TIM’s upcoming shareholder meeting on May 4th. Inadequate governance and poor stewardship have imposed a heavy cost on TIM’s stakeholders for too long. Vivendi’s repeated missteps and self-serving behaviour have eroded the value of TIM’s shares and destroyed shareholder trust. The question being put to TIM shareholders on May 4th is: can you entrust your investment to Vivendi as long-term stewards of your capital and this company moving forward? Shareholders should take the opportunity to correct a governance structure rife with conflict and demand high quality and independent stewardship at the Board level. Shareholders have the opportunity to remove an otherwise permanent, persisting and pervasive impairment of value. This pivotal vote offers a textbook opportunity to put

Javier Gómez Noya Chooses ROKA Eyewear26.4.2018 21:15Tiedote

ROKA, the Austin-based performance design company, has announced a multiyear eyewear partnership with eight-time triathlon world champion and Olympic silver medalist Javier Gómez Noya, expanding their existing relationship for technical race apparel and equipment. Starting in 2018, Gómez will train and race in ROKA’s eyewear, the lightest, most advanced performance optics in the world, in the pursuit of his first Ironman World Championship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180426006510/en/ Javier Gómez Noya Chooses ROKA Eyewear (Photo: Business Wire) “I first tried the Advanced Performance eyewear while I was at ROKA’s headquarters in Texas, and right away I knew they were the glasses I should be using everyday,” Gómez Noya says. “There’s nothing like them in terms of weight, retention, and quality of vision. Whether cycling or running, you can’t feel that you’re wearing them but you have an incredible field of

Egyptian Singer Becomes First Woman to Perform Before a Mixed Crowd in Saudi Arabia26.4.2018 20:55Tiedote

History was made in Saudi Arabia on Wednesday as a female singer performed before a mixed audience for the first time in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180426006471/en/ Egypt’s National Arab Music Ensemble of the Egyptian Opera House debuted in Saudi Arabia with the singer Nihad Fathy performing before a 2,500-strong audience in Riyadh. This is the first time a woman singer performed on stage in the Kingdom before a mixed crowd. (Photo courtesy of GCA Saudi Arabia.) Egypt’s National Arab Music Ensemble (AME) of the Egyptian Opera House debuted in the Kingdom with the singer Nihad Fathy performing before a 2,500-strong audience at King Fahad Cultural Center in Riyadh. The crowd broke into a rapturous applause as she took to the stage. The Egyptian Opera House ensemble, which was led by famous conductor Moustafa Helmy, comprised 45 male and female musicians and singers, including the star singers A

Pharnext Appoints Amit Kohli as Chief Operating Officer26.4.2018 19:00Tiedote

Regulatory News: Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big genomic data and artificial intelligence, today announced the appointment of Amit Kohli, a senior healthcare industry executive, as Chief Operating Officer (COO). Mr. Kohli is responsible for leading Pharnext’s corporate strategy and operations. “Amit is a seasoned leader with over 20 years’ experience in the healthcare industry, and we are thrilled he is joining Pharnext,” said Prof. Daniel Cohen, M.D., Ph.D., Co-Founder and Chief Executive Officer of Pharnext. “We are deeply impressed with Amit’s results-oriented track record, and his ability to drive business strategy and operations across the pharma, medtech and clinical diagnostics sectors. We believe Pharnext will greatly benefit from his extensive cross-functional leadership experience especially as our first-in-class orphan drug, PXT3003, for the

Leading Marine Container Leasing Management Team Launches Global Container International26.4.2018 18:33Tiedote

Jeffrey Gannon and Adrian Dunner, in partnership with investment vehicles managed by Wafra Inc., today announced the formation of Global Container International LLC (“Global”), a new marine container leasing platform headquartered in Boston, Massachusetts and with representation in Hong Kong, Shanghai, Singapore, Antwerp, Taipei, and Seoul. With a near-term goal of building a fleet of 1 million TEU (twenty-foot equivalent units), Global is positioned to provide its customers a reliable alternative source of capital and containers for lease. Jeffrey Gannon serves as Chief Executive Officer of Global, and Adrian Dunner serves as Chief Operating Officer. Together, they offer clients a combined 50 years of experience backed by successful track records in the container leasing industry. Global will invest in marine containers and related equipment made available for lease under a wide range of structures to meet customer needs. Investments will include new build containers, portfolio purcha

TimeXtender Discovery Hub® is Now Microsoft Azure Certified26.4.2018 17:00Tiedote

TimeXtender, a recognized global software company enabling instant access to any type of data in the organization to support advanced analytics and artificial intelligence (AI), today announced that its Discovery Hub® solution has been tested, approved and certified for readiness and compatibility to run in Microsoft Azure environments. With this certification, Discovery Hub® is now a trusted application that is available in the Microsoft Azure Marketplace. The Azure Marketplace is an extensive catalog of products from independent software vendors (ISVs). Azure Marketplace allows IT professionals and developers to confidently search for Microsoft Azure certified products and solutions. “To be published in the Azure Marketplace, a solution goes through a number of certification steps to validate the platform, solution and software,” said Heine Krog Iversen, CEO at TimeXtender. “Given these requirements, we’re pleased that Discovery Hub® has been certified to run on Microsoft Azure. This

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme